Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Maravai Lifesciences Holdings Inc Cl A (MRVI)

Maravai Lifesciences Holdings Inc Cl A (MRVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics ACCESSWIRE - Thu Jun 20, 4:15AM CDT

- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability -- Applied DNA Secures Commercial Linea RNAP Quantity Sufficient...

APDN : 0.3800 (-13.66%)
MRVI : 6.80 (-0.58%)
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics ACCESSWIRE - Thu Jun 20, 4:15AM CDT

- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability -- Applied DNA Secures Commercial Linea RNAP Quantity Sufficient...

APDN : 0.3800 (-13.66%)
MRVI : 6.80 (-0.58%)
Maravai LifeSciences (MRVI) Q1 2024 Earnings Call Transcript Motley Fool - Thu May 9, 2:15AM CDT

MRVI earnings call for the period ending March 31, 2024.

MRVI : 6.80 (-0.58%)
Maravai LifeSciences (MRVI) Q4 2023 Earnings Call Transcript Motley Fool - Thu Feb 22, 7:30PM CST

MRVI earnings call for the period ending December 31, 2023.

MRVI : 6.80 (-0.58%)
Maravai LifeSciences (MRVI) Q3 2023 Earnings Call Transcript Motley Fool - Tue Nov 7, 2023

MRVI earnings call for the period ending September 30, 2023.

MRVI : 6.80 (-0.58%)
Wall Street - shutterstock_94127350
Stock Index Futures Plunge as China Trade Data Disappoints, Moody's Downgrades U.S. Banks Barchart - Tue Aug 8, 2023

September S&P 500 futures (ESU23) are down -0.45%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.49% this morning as fresh worries about China’s economic rebound and the state of U.S. banks...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
BRK.A : 609,500.00 (-0.19%)
SOVO : 22.98 (+0.13%)
TSN : 56.49 (-1.28%)
TSLA : 240.27 (+3.90%)
LLY : 893.12 (-1.50%)
UPS : 135.32 (+0.30%)
ZTS : 176.59 (+1.02%)
DUK : 100.01 (+0.20%)
GLEN.LN : 477.400 (+2.39%)
CHGG : 2.93 (+1.38%)
Maravai LifeSciences (MRVI) Q2 2023 Earnings Call Transcript Motley Fool - Tue Aug 8, 2023

MRVI earnings call for the period ending June 30, 2023.

MRVI : 6.80 (-0.58%)
Maravai LifeSciences (MRVI) Q1 2023 Earnings Call Transcript Motley Fool - Tue May 9, 2023

MRVI earnings call for the period ending March 31, 2023.

MRVI : 6.80 (-0.58%)
2 Top Biotech Stocks to Buy In March and Hold Forever Motley Fool - Mon Mar 13, 2023

Their price is right, and their future is bright.

MRNA : 115.32 (-1.49%)
MRVI : 6.80 (-0.58%)
Don't Miss Out on These 2 Undervalued Stocks With Huge Growth Potential Motley Fool - Thu Mar 2, 2023

There isn't much that's stopping them from penetrating their markets globally.

INMD : 17.56 (+0.86%)
MRVI : 6.80 (-0.58%)

Barchart Exclusives

The Spring Doldrums in The Gold Market May Be Changing Soon Barchart - 12 minutes ago
Over the past five years, data shows distinct patterns in the seasonality of gold prices. September has consistently been weak, with prices often closing lower than they opened, suggesting a decrease in market confidence or a shift in investment focus. In contrast, due to increased buying, July has shown a higher probability of gold prices closing above their opening mark. Are the Spring doldrums in gold prices ready to change to higher prices? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot